share_log

Rayont Inc- RAYT- Reports 10-Q for the Six-Month Ending December 31, 2021, Financial Results.

Rayont Inc- RAYT- Reports 10-Q for the Six-Month Ending December 31, 2021, Financial Results.

Rayont Inc-RAYT-报告截至2021年12月31日的6个月的10-Q财务业绩。
GlobeNewswire ·  2022/02/24 09:07

Palo Alto, California, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Rayont Inc. ("Rayont" or the "Company") (OTC PINK: RAYT), an international healthcare company specializing in the manufacturing, distribution of alternative medicine products and services across the entire value chain, today reported financial results for the six-month ended December 31, 2021.

加利福尼亚州帕洛阿尔托,2022年2月24日(Global Newswire)--Rayont Inc.(“Rayont”or“Company”)(场外交易市场代码:RAYT)是一家专门在整个价值链上制造、分销替代医学产品和服务的国际医疗保健公司,该公司今天公布了截至2021年12月31日的6个月的财务业绩。

Business Highlights Within the Six-Month ended December 31, 2021:

内部业务亮点-截至上月(二零二零年十二月三十一日)1:

Ms. Marshini Moodley, Director and CFO, said, "We recorded improvements across most aspects of the business for the period ending December 31, 2021 compared to same period last year. The key highlight for the last three months is moving into "a state of the art manufacturing facility at 32 French Avenue , Brendale in Brisbane Australia " and our ability to maintain the quarterly revenues despite downtime in production."

董事首席财务官马什尼·穆德利女士说:“与去年同期相比,我们在截至2021年12月31日的一段时间里,业务的大部分方面都有所改善。过去三个月的主要亮点是搬进了‘位于澳大利亚布里斯班布伦代尔法兰西大道32号的最先进的制造工厂’,以及我们在停产的情况下仍能保持季度收入的能力。”

Six-month Ending December 31, 2021, Financial Results:

-月末(二零二零年十二月三十一日)1,财务业绩:

    Six Months Ended December 31,  
    2021     2020  
Revenues   $ 1,361,887     $ 1,196,240  
Gross Profit   $ 690,466     $ 524,790  
截至的月份十二月 31,
2021 2020
收入 $ 1,361,887 $ 1,196,240
毛利 $ 690,466 $ 524,790

Improved Balance Sheet Results

资产负债表业绩改善

      December 31,
2021
      June 30,
2021
 
Cash   $ 8,320     $ 243,610  
Total Assets   $ 7,955,972     $ 7,157,352  
Total Liabilities   $ 3,607,299     $ 3,430,326  
Total Stockholders' Equity   $ 4,348,673     $ 3,727,026  
十二月31,
2021
六月三十日,
2021
现金 $ 8,320 $ 243,610
总资产 $ 7,955,972 $ 7,157,352
总负债 $ 3,607,299 $ 3,430,326
股东权益总额 $ 4,348,673 $ 3,727,026

Marshini Moodley added, "Our 10-Q performance reflecting increased revenues, total asset portfolio and total stockholders' equity. The debt ratio is decreased from 48% that was on June 30, 2021, to 45% as of December 31, 2021. Our cash reserves have decreased due to capital investments and servicing short term loan interest. The focus this quarter is to refinance the properties from short term loans with private lenders to long term loans with competitive interest rates."

Marshini Moodley补充说,“我们的10-Q业绩反映了收入、总资产组合和总股东权益的增加。负债率从2021年6月30日的48%下降到2021年12月31日的45%。由于资本投资和偿还短期贷款利息,我们的现金储备有所减少。本季度的重点是以有竞争力的利率对物业进行再融资,从私人贷款人的短期贷款转向长期贷款。”

Strategies for Growth

增长战略

During this financial year we continue to undertake several key activities aimed to improve the overall performance of Rayont Inc namely:

在本财政年度,我们继续开展旨在改善Rayont Inc.整体业绩的几项关键活动,即:

  • Seek to acquire revenue and profit producing complementary business to Prema Life Australia. This would improve the utilization of increased capacity.
  • Launch Health Script telehealth platform for naturopaths globally with key markets focus Australia and the USA.
  • Launch Rayont Coin as global reward platform for our consumers aimed to enhance customer experience and loyalty.
  • Start operations of Prema Life USA aimed to grow overall revenues and expand into the USA market.
  • 寻求获得收入和利润,生产澳大利亚普雷马人寿的补充业务。这将提高增加的产能的利用率。
  • 为全球自然疗法推出Health Script远程保健平台,主要市场集中在澳大利亚和美国。
  • 推出Rayont Coin作为我们消费者的全球奖励平台,旨在提升客户体验和忠诚度。
  • Prema Life USA的初创业务旨在增加整体收入,并向美国市场扩张。

These activities are being worked on and we will communicate their completions as we achieve them.

这些活动正在进行中,我们将在完成后通报它们的完成情况。

About Rayont Inc.

A回合赛人造丝Inc.

Rayont, Inc. (RAYT) is a public traded company incorporated in Nevada, USA since its inception in 2011. In 2018, the Company repositioned itself to focus on healthcare including the manufacturing, distribution of alternative medicine products and services across the entire value chain.

Rayont,Inc.(RAYT)是一家自2011年成立以来在美国内华达州注册的上市公司。2018年,该公司重新定位,专注于医疗保健,包括在整个价值链上制造、分销替代医学产品和服务。

Longer term, it has also invested in a groundbreaking cancer treatment technology through an exclusive license arrangement for the Sub-Saharan African territories.

从长远来看,它还通过撒哈拉以南非洲领土的独家许可安排投资了一项突破性的癌症治疗技术。

Headquartered in Australia with expanding operations internationally, Rayont`s purpose is "Making Natural Products to Improve People`s Health". We do this by investing in early research and development, establishing high quality manufacturing assets for regional distribution and operating across the alternative medicine value chain.

总部设在澳大利亚,并在国际上拓展业务,雷扬特的宗旨是“制造天然产品,增进人们的健康”。我们通过投资于早期研发、建立用于区域分销的高质量制造资产以及跨替代药物价值链运营来做到这一点。

Our underlying strategy is to grow organically, selectively acquire, scale profitable assets and improve efficiency through digitalization.

我们的基本战略是通过数字化实现有机增长、有选择地收购、扩大盈利资产规模并提高效率。

For further information, please visit 

欲了解更多信息,请访问

SAFE HARBOR

安全港

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, are subject to Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbors created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.

本新闻稿中的某些陈述可能包含1933年“证券法”第175条规定的前瞻性信息,受1934年“证券交易法”第3b-6条的约束,并受这些规定所创造的安全港的约束。本新闻稿中包含的除事实陈述外的所有陈述,包括但不限于有关公司潜在未来计划和目标的陈述,均为前瞻性陈述,涉及风险和不确定因素。不能保证这样的陈述将被证明是准确的,其他结果和进一步的事件可能与这些陈述中预期的大不相同。未来的事件和实际结果可能与前瞻性陈述中陈述的、预期的或潜在的大不相同。

Company Contact:
Investor Relations
ir@rayont.com

公司联系人:
投资者关系
邮箱:ir@rayont.com


声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发